BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shen DD, Pang JR, Bi YP, Zhao LF, Li YR, Zhao LJ, Gao Y, Wang B, Wang N, Wei L, Guo H, Liu HM, Zheng YC. LSD1 deletion decreases exosomal PD-L1 and restores T-cell response in gastric cancer. Mol Cancer 2022;21:75. [PMID: 35296335 DOI: 10.1186/s12943-022-01557-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Cao Y, Xu P, Shen Y, Wu W, Chen M, Wang F, Zhu Y, Yan F, Gu W, Lin Y. Exosomes and cancer immunotherapy: A review of recent cancer research. Front Oncol 2023;12. [DOI: 10.3389/fonc.2022.1118101] [Reference Citation Analysis]
2 Xia J, Li S, Liu S, Zhang L. Aldehyde dehydrogenase in solid tumors and other diseases: Potential biomarkers and therapeutic targets. MedComm (2020) 2023;4:e195. [PMID: 36694633 DOI: 10.1002/mco2.195] [Reference Citation Analysis]
3 Zhang Y, Chen J, Liu H, Mi R, Huang R, Li X, Fan F, Xie X, Ding J. The role of histone methylase and demethylase in antitumor immunity: A new direction for immunotherapy. Front Immunol 2023;13. [DOI: 10.3389/fimmu.2022.1099892] [Reference Citation Analysis]
4 Kim JH, Lee CH, Baek MC. Dissecting exosome inhibitors: therapeutic insights into small-molecule chemicals against cancer. Exp Mol Med 2022;54:1833-43. [PMID: 36446847 DOI: 10.1038/s12276-022-00898-7] [Reference Citation Analysis]
5 Moreno-Andrés D, Holl K, Antonin W. The second half of mitosis and its implications in cancer biology. Semin Cancer Biol 2022;88:1-17. [PMID: 36436712 DOI: 10.1016/j.semcancer.2022.11.013] [Reference Citation Analysis]
6 Zhao L, Yu L, Wang X, He J, Zhu X, Zhang R, Yang A. Mechanisms of function and clinical potential of exosomes in esophageal squamous cell carcinoma. Cancer Letters 2022. [DOI: 10.1016/j.canlet.2022.215993] [Reference Citation Analysis]
7 Matsuzaka Y, Yashiro R. Molecular Docking and Intracellular Translocation of Extracellular Vesicles for Efficient Drug Delivery. IJMS 2022;23:12971. [DOI: 10.3390/ijms232112971] [Reference Citation Analysis]
8 Liu Y, Li C, Lu Y, Liu C, Yang W. Tumor microenvironment-mediated immune tolerance in development and treatment of gastric cancer. Front Immunol 2022;13:1016817. [DOI: 10.3389/fimmu.2022.1016817] [Reference Citation Analysis]
9 Gao Z, Ling X, Shi C, Wang Y, Lin A. Tumor immune checkpoints and their associated inhibitors. J Zhejiang Univ Sci B 2022;23:823-43. [PMID: 36226537 DOI: 10.1631/jzus.B2200195] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Niu Z, Jin R, Zhang Y, Li H. Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials. Signal Transduct Target Ther 2022;7:353. [PMID: 36198685 DOI: 10.1038/s41392-022-01200-x] [Reference Citation Analysis]
11 Yang G, Liu Y, Ding L, Tao F, Zhu M, Shi Z, Wen J, Niu M, Li X, Xu Z, Qin W, Fei C, Chen J. A state-of-the-art review on LSD1 and its inhibitors in breast cancer: Molecular mechanisms and therapeutic significance. Front Pharmacol 2022;13:989575. [DOI: 10.3389/fphar.2022.989575] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Yang C, Li D, Zang S, Zhang L, Zhong Z, Zhou Y. Mechanisms of carcinogenic activity triggered by lysine-specific demethylase 1A. Front Pharmacol 2022;13:955218. [DOI: 10.3389/fphar.2022.955218] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Tang Q, Yang S, He G, Zheng H, Zhang S, Liu J, Wei S, Fan Q, Peng X, Li X, Zhang D, Yang L, Li H. Tumor-derived exosomes in the cancer immune microenvironment and cancer immunotherapy. Cancer Lett 2022;:215823. [PMID: 35835409 DOI: 10.1016/j.canlet.2022.215823] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]